Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study is to assess patient satisfaction with the inhaler attributes of the re-usable Respimat SMI (Spiriva, Striverdi or Spiolto) in patients with COPD, including patients who are Respimat SMI-experienced and Respimat SMI-naïve. This study also aims to examine patient preference for the re-usable Respimat SMI compared to the disposable Respimat SMI in Respimat SMI-experienced patients switching from a disposable to a re-usable Respimat SMI product at study entry.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Respimat SMI-experienced: Switching to re-usable Respimat | patients who had been on maintenance treatment with a disposable Respimat and who switched to a re-usable Respimat SMI at study entry. |
| |
| Respimat SMI-naïve | patients who have not previously used a Respimat SMI product and receive their first prescription at study entry |
| |
| Respimat SMI-experienced: Maintenance treatment | patients who have been on maintenance treatment with a Respimat SMI product and receive a refill prescription at study entry. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Respimat | Drug | Soft Mist Inhaler product |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mean Total Patient Satisfaction and Preference Questionnaire (PASAPQ) Score | Total PASAPQ score is a measure of patient's satisfaction regarding the handling of the re-usable Respimat® SMI. The total score was the sum of the 13 items related to Performance and Convenience PASAPG domains (7 items for Performance domain: Q 1-5, 10-11, and 6 items for convenience domain: Q6-9, 12-13). Each PASAPQ item had response options ranging from 1 (very dissatisfied) to 7 (very satisfied). To calculate the total and domain score, the items within each domain were first summed and then transformed to a 0 (least) or 100 (most) point scale, with higher scores indicating greater satisfaction: Performance score = 100 *[(Q1+Q2 +Q3+ Q4+Q5+Q10+Q11)-7] /(49-7) Convenience score = 100 *[(Q6+ Q7+Q8+Q9+Q12+Q13)-6] / (42-6) Total score = 100 *[(Q1+Q2 +Q3+Q4+ Q5+Q6 + Q7+Q8+ Q9+Q10+Q11+Q12+Q13)-13] / (91-13) | At follow-up assessment, 4 to 6 weeks after baseline. |
| Measure | Description | Time Frame |
|---|---|---|
| Total Performance PASAPQ Score for All Patients at Study End (Follow-up Assessment) | The performance domain score of PASAPQ contained 7 items (Q 1-5 and 10-11), each item had response options ranging from 1 (very dissatisfied) to 7 (very satisfied). To calculate the domain score, the items were first summed and then transformed to a 0 (least) to 100 (most) point scale, with higher scores indicating greater satisfaction: Performance score = 100 * [(Q1+ Q2+Q3+Q4+Q5+Q10+Q11)-7] / (49-7) |
Not provided
Inclusion Criteria:
Patients fulfilling all the following inclusion criteria will be eligible for participation in the study:
Exclusion Criteria:
Patients fulfilling any of the following exclusion criteria will not be eligible for participation in the study:
Not provided
Not provided
Not provided
The study is planned that approximately with 250 Chronic Obstructive Pulmonary Disease (COPD) patients (Respimat SMI-experienced and Respimat SMI-naïve) from Europe will be enrolled in this study.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Brussels - UNIV UZ Brussel | Brussels | 1090 | Belgium | |||
| Clinique Notre-Dame de Grâce |
Not provided
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://trials.boehringer-ingelheim.com/trial\_results/ clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".
Also, Researchers can use the following link http://trials.boehringeringelheim.com/ to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
The data shared are the raw clinical study data sets.
After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
262 patients were enrolled into the study, whereof 2 patients were enrolment failures as they did not meet eligibility criteria or received a disposable inhaler. Subjects were not to be allocated to a treatment group if any of the entry criteria were violated.
A real-world, non-interventional study to assess the satisfaction of chronic obstructive pulmonary disease (COPD) patients with inhaler attributes and preferences for re-usable Respimat® Soft Mist Inhaler (SMI).
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Respimat® SMI-experienced: Maintenance With Re-usable SMI | Chronic obstructive pulmonary disease (COPD) patients who had been on maintenance treatment with a re-usable Respimat Sof Mist Inhaler (SMI) product (Spiriva®, Striverdi®, or Spiolto®) at study entry. Patients were followed from the time of study entry (enrollment visit) for a period of approximately 4 to 6 weeks (study period). |
| FG001 | Respimat® SMI-experienced: Switching to Re-usable SMI | Chronic obstructive pulmonary disease (COPD) patients who had been on maintenance treatment with a disposable Respimat and who switched to a re-usable Respimat SMI at study entry. Patients were followed from the time of study entry (enrolment visit) for a period of approximately 4 to 6 weeks (study period). |
| FG002 | Respimat® SMI-naïve | Chronic obstructive pulmonary disease (COPD) patients who had not previously used a Respimat SMI product and had received their first prescription for a re-usable Respimat SMI product at study entry. Patients were followed from the time of study entry (enrolment visit) for a period of approximately 4 to 6 weeks (study period). |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Full Analysis Set (FAS): All enrolled patients who met all the eligibilty criteria of the study and who had received at least one dose of ther re-usable Respimat SMI product during the study period.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Respimat® SMI-experienced: Maintenance With Re-usable SMI | Chronic obstructive pulmonary disease (COPD) patients who had been on maintenance treatment with a re-usable Respimat Sof Mist Inhaler (SMI) product (Spiriva®, Striverdi®, or Spiolto®) at study entry. Patients were followed from the time of study entry (enrollment visit) for a period of approximately 4 to 6 weeks (study period). |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Mean Total Patient Satisfaction and Preference Questionnaire (PASAPQ) Score | Total PASAPQ score is a measure of patient's satisfaction regarding the handling of the re-usable Respimat® SMI. The total score was the sum of the 13 items related to Performance and Convenience PASAPG domains (7 items for Performance domain: Q 1-5, 10-11, and 6 items for convenience domain: Q6-9, 12-13). Each PASAPQ item had response options ranging from 1 (very dissatisfied) to 7 (very satisfied). To calculate the total and domain score, the items within each domain were first summed and then transformed to a 0 (least) or 100 (most) point scale, with higher scores indicating greater satisfaction: Performance score = 100 *[(Q1+Q2 +Q3+ Q4+Q5+Q10+Q11)-7] /(49-7) Convenience score = 100 *[(Q6+ Q7+Q8+Q9+Q12+Q13)-6] / (42-6) Total score = 100 *[(Q1+Q2 +Q3+Q4+ Q5+Q6 + Q7+Q8+ Q9+Q10+Q11+Q12+Q13)-13] / (91-13) | Patients in the Full Analysis Set (FAS) who have available data for this endpoint. | Posted | Mean | 95% Confidence Interval | Score on a scale | At follow-up assessment, 4 to 6 weeks after baseline. |
|
From study entry until end of study, up to 6 weeks.
Full Analysis Set (FAS): All enrolled patients who met all the eligibility criteria of the study and who had received at least one dose of ther re-usable Respimat SMI product during the study period.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Respimat® SMI-experienced: Maintenance With Re-usable SMI | Chronic obstructive pulmonary disease (COPD) patients who had been on maintenance treatment with a re-usable Respimat Sof Mist Inhaler (SMI) product (Spiriva®, Striverdi®, or Spiolto®) at study entry. Patients were followed from the time of study entry (enrollment visit) for a period of approximately 4 to 6 weeks (study period). |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Boehringer Ingelheim Call Center | Boehringer Ingelheim | 1-800-243-0127 | clintriage.rdg@boehringer-ingelheim.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jun 11, 2019 | Feb 5, 2021 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Oct 10, 2019 | Feb 5, 2021 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069447 | Tiotropium Bromide |
| C549647 | olodaterol |
| C000611386 | tiotropium-olodaterol |
| ID | Term |
|---|---|
| D012602 | Scopolamine Derivatives |
| D014326 | Tropanes |
| D053961 | Azabicyclo Compounds |
| D001372 | Aza Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
| At follow-up assessment, 4 to 6 weeks after baseline. |
| Total Convenience PASAPQ Score for All Patients at Study End (Follow-up Assessment) | The convenience domain score of PASAPQ contained 6 items (Question 6-9 and 12-13), each item had response options ranging from 1 (very dissatisfied) to 7 (very satisfied). To calculate the domain score, the items were first summed and then transformed to a 0 (least) to 100 (most) point scale, with higher scores indicating greater satisfaction: Convenience score = 100 * [(Q6+Q7+Q8+Q9+Q12+Q13)-6] / (42-6) | At follow-up assessment, 4 to 6 weeks after baseline. |
| Overall Satisfaction Question With Inhaler for All Patients at Study End (Follow-up Assessment) | The overall satisfaction score of the PASAPQ asked for the overall satisfaction with the device used in the study (Question 14), answered using a 7-point scale ranging from 1 (very dissatisfied) to 7 (very satisfied). Reported is the number of patients by category. | At follow-up assessment, 4 to 6 weeks after baseline. |
| Question on Willingness to Continue With Inhaler for All Patients at Study End (Follow-up Assessment) | To assess the willingness to continue with inhaler, the following questions was asked: "How would you feel about continuing to use the inhaler?", using a value from 0-100, with zero indicating that the patient is not willing to continue using the inhaler and 100 indicating that the patient is definitely willing to continue using the inhaler. | At follow-up assessment, 4 to 6 weeks after baseline. |
| Questions on Ease of Handling of the Re-usable Respimat SMI for All Patients at Study End (Follow-up Assessment) | 10 Questions regarding the Ease of Handling were asked, using a 7 point scale ranging from 1 (very dissatisfied) to 7 (very satisfied). Reported is the number of patients by answer category. | At follow-up assessment, 4 to 6 weeks after baseline. |
| Difference in the Mean Total PASAPQ Score Between Study Entry and Study End in Respimat SMI-experienced Patients Who Switched From a Disposable to a Re-usable Respimat SMI Product | Difference in the mean Total PASAPQ score between study entry (baseline visit) and at study end (follow-up assessment) in Respimat SMI-experienced patients who switched from a disposable to a re-usable Respimat SMI product at study entry. The total score was the sum of the 13 items related to Performance and Convenience PASAPG domains (7 items for Performance domain: Q 1-5, 10-11, and 6 items for convenience domain: Q6-9, 12-13). Each PASAPQ item had response options ranging from 1 (very dissatisfied) to 7 (very satisfied). To calculate the total and domain score, the items within each domain were first summed and then transformed to a 0 (least) or 100 (most) point scale, with higher scores indicating greater satisfaction. | At study entry (baseline) and at study end (4 to 6 weeks after baseline). |
| Number of Patients With Preference for Re-usable or Disposable Respimat SMI at Study End in Respimat SMI-experienced Patients Who Switched From a Disposable to a Re-usable Respimat SMI Product | Number of patients with preference for re-usable or disposable Respimat SMI at study end (follow-up assessment), in Respimat SMI-experienced patients who switched from a disposable to a re-usable Respimat SMI product at study entry. To assess the preference for inhaler, following question was asked: "Comparing the re-usable with disposable inhaler, which inhaler do you prefer to use?" | At follow-up assessment, 4 to 6 weeks after baseline. |
| Gosselies |
| 6041 |
| Belgium |
| Roeselare - HOSP AZ Delta | Menen | 8930 | Belgium |
| Hvidovre Hospital | Hvidovre | 2650 | Denmark |
| Vejle Hospital | Vejle | 7100 | Denmark |
| TYKS, Keuhkosairauksien klinikka, Turku | Turku | 20520 | Finland |
| Universitätsklinikum Aachen, AöR | Aachen | 52074 | Germany |
| MECS Research GmbH, Berlin | Berlin | 12203 | Germany |
| KPPK GmbH, Studienzentrum | Koblenz | 56068 | Germany |
| Pneumologiezentrum Leipzig | Leipzig | 04207 | Germany |
| Pneumologische Schwerpunktpraxis, 23558 Lübeck | Lübeck | 23558 | Germany |
| Amphia Ziekenhuis | Breda | 4818 CK | Netherlands |
| Zuyderland Medisch Centrum | Heerlen | 6419 PC | Netherlands |
| Medisch Centrum Leeuwarden | Leeuwarden | 8934 AD | Netherlands |
| Franciscus Gasthuis | Rotterdam | 3045 PM | Netherlands |
| Gelre Ziekenhuis Zutphen | Zutphen | 7207 AE | Netherlands |
| Frisk Utvikling Helse AS | Elverum | N-2402 | Norway |
| Hisøy Legesenter | Kolbjørnsvik | N-4816 | Norway |
| Lambertseter Legesenter | Oslo | N-1157 | Norway |
| Svelvik Legesenter | Svelvik | N-3060 | Norway |
| BG001 | Respimat® SMI-experienced: Switching to Re-usable SMI | Chronic obstructive pulmonary disease (COPD) patients who had been on maintenance treatment with a disposable Respimat and who switched to a re-usable Respimat SMI at study entry. Patients were followed from the time of study entry (enrolment visit) for a period of approximately 4 to 6 weeks (study period). |
| BG002 | Respimat® SMI-naïve | Chronic obstructive pulmonary disease (COPD) patients who had not previously used a Respimat SMI product and had received their first prescription for a re-usable Respimat SMI product at study entry. Patients were followed from the time of study entry (enrolment visit) for a period of approximately 4 to 6 weeks (study period). |
| BG003 | Total | Total of all reporting groups |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| OG000 | Respimat® SMI-experienced: Maintenance With Re-usable SMI | Chronic obstructive pulmonary disease (COPD) patients who had been on maintenance treatment with a re-usable Respimat Sof Mist Inhaler (SMI) product (Spiriva®, Striverdi®, or Spiolto®) at study entry. Patients were followed from the time of study entry (enrollment visit) for a period of approximately 4 to 6 weeks (study period). |
| OG001 | Respimat® SMI-experienced: Switching to Re-usable SMI | Chronic obstructive pulmonary disease (COPD) patients who had been on maintenance treatment with a disposable Respimat and who switched to a re-usable Respimat SMI at study entry. Patients were followed from the time of study entry (enrolment visit) for a period of approximately 4 to 6 weeks (study period). |
| OG002 | Respimat® SMI-naïve | Chronic obstructive pulmonary disease (COPD) patients who had not previously used a Respimat SMI product and had received their first prescription for a re-usable Respimat SMI product at study entry. Patients were followed from the time of study entry (enrolment visit) for a period of approximately 4 to 6 weeks (study period). |
|
|
| Secondary | Total Performance PASAPQ Score for All Patients at Study End (Follow-up Assessment) | The performance domain score of PASAPQ contained 7 items (Q 1-5 and 10-11), each item had response options ranging from 1 (very dissatisfied) to 7 (very satisfied). To calculate the domain score, the items were first summed and then transformed to a 0 (least) to 100 (most) point scale, with higher scores indicating greater satisfaction: Performance score = 100 * [(Q1+ Q2+Q3+Q4+Q5+Q10+Q11)-7] / (49-7) | Patients in the Full Analysis Set (FAS) who have available data for this endpoint. | Posted | Mean | Standard Deviation | Score on a scale | At follow-up assessment, 4 to 6 weeks after baseline. |
|
|
|
| Secondary | Total Convenience PASAPQ Score for All Patients at Study End (Follow-up Assessment) | The convenience domain score of PASAPQ contained 6 items (Question 6-9 and 12-13), each item had response options ranging from 1 (very dissatisfied) to 7 (very satisfied). To calculate the domain score, the items were first summed and then transformed to a 0 (least) to 100 (most) point scale, with higher scores indicating greater satisfaction: Convenience score = 100 * [(Q6+Q7+Q8+Q9+Q12+Q13)-6] / (42-6) | Patients in the Full Analysis Set (FAS) who have available data for this endpoint. | Posted | Mean | Standard Deviation | Score on a scale | At follow-up assessment, 4 to 6 weeks after baseline. |
|
|
|
| Secondary | Overall Satisfaction Question With Inhaler for All Patients at Study End (Follow-up Assessment) | The overall satisfaction score of the PASAPQ asked for the overall satisfaction with the device used in the study (Question 14), answered using a 7-point scale ranging from 1 (very dissatisfied) to 7 (very satisfied). Reported is the number of patients by category. | Patients in the Full Analysis Set (FAS) who have available data for this endpoint. | Posted | Count of Participants | Participants | At follow-up assessment, 4 to 6 weeks after baseline. |
|
|
|
| Secondary | Question on Willingness to Continue With Inhaler for All Patients at Study End (Follow-up Assessment) | To assess the willingness to continue with inhaler, the following questions was asked: "How would you feel about continuing to use the inhaler?", using a value from 0-100, with zero indicating that the patient is not willing to continue using the inhaler and 100 indicating that the patient is definitely willing to continue using the inhaler. | Patients in the Full Analysis Set (FAS) who have available data for this endpoint. | Posted | Mean | Standard Deviation | Score on a scale | At follow-up assessment, 4 to 6 weeks after baseline. |
|
|
|
| Secondary | Questions on Ease of Handling of the Re-usable Respimat SMI for All Patients at Study End (Follow-up Assessment) | 10 Questions regarding the Ease of Handling were asked, using a 7 point scale ranging from 1 (very dissatisfied) to 7 (very satisfied). Reported is the number of patients by answer category. | Full Analysis Set (FAS): All enrolled patients who met all the eligibility criteria of this study and who had received at least one dose of their re-usable Respimat SMI product during the study. Missing patients did not perform the Follow-up assesment or who did not perform the Ease of Handling assessment at Follow-Up assessment. | Posted | Count of Participants | Participants | At follow-up assessment, 4 to 6 weeks after baseline. |
|
|
|
| Secondary | Difference in the Mean Total PASAPQ Score Between Study Entry and Study End in Respimat SMI-experienced Patients Who Switched From a Disposable to a Re-usable Respimat SMI Product | Difference in the mean Total PASAPQ score between study entry (baseline visit) and at study end (follow-up assessment) in Respimat SMI-experienced patients who switched from a disposable to a re-usable Respimat SMI product at study entry. The total score was the sum of the 13 items related to Performance and Convenience PASAPG domains (7 items for Performance domain: Q 1-5, 10-11, and 6 items for convenience domain: Q6-9, 12-13). Each PASAPQ item had response options ranging from 1 (very dissatisfied) to 7 (very satisfied). To calculate the total and domain score, the items within each domain were first summed and then transformed to a 0 (least) or 100 (most) point scale, with higher scores indicating greater satisfaction. | FAS: Respimat SMI-experience patients who switched from a disposable to a re-usable Respimat SMI product at study entry and with available data for this endpoint. | Posted | Mean | Standard Deviation | Score on a scale | At study entry (baseline) and at study end (4 to 6 weeks after baseline). |
|
|
|
| Secondary | Number of Patients With Preference for Re-usable or Disposable Respimat SMI at Study End in Respimat SMI-experienced Patients Who Switched From a Disposable to a Re-usable Respimat SMI Product | Number of patients with preference for re-usable or disposable Respimat SMI at study end (follow-up assessment), in Respimat SMI-experienced patients who switched from a disposable to a re-usable Respimat SMI product at study entry. To assess the preference for inhaler, following question was asked: "Comparing the re-usable with disposable inhaler, which inhaler do you prefer to use?" | FAS: Respimat SMI-experience patients who switched from a disposable to a re-usable Respimat SMI product at study entry and with available data for this endpoint. | Posted | Count of Participants | Participants | At follow-up assessment, 4 to 6 weeks after baseline. |
|
|
|
| 0 |
| 133 |
| 0 |
| 133 |
| 0 |
| 133 |
| EG001 | Respimat® SMI-experienced: Switching to Re-usable SMI | Chronic obstructive pulmonary disease (COPD) patients who had been on maintenance treatment with a disposable Respimat and who switched to a re-usable Respimat SMI at study entry. Patients were followed from the time of study entry (enrolment visit) for a period of approximately 4 to 6 weeks (study period). | 0 | 70 | 0 | 70 | 0 | 70 |
| EG002 | Respimat® SMI-naïve | Chronic obstructive pulmonary disease (COPD) patients who had not previously used a Respimat SMI product and had received their first prescription for a re-usable Respimat SMI product at study entry. Patients were followed from the time of study entry (enrolment visit) for a period of approximately 4 to 6 weeks (study period). | 0 | 56 | 0 | 56 | 0 | 56 |
Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review Prior to any Submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI´s intellectual property rights.
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009930 |
| Organic Chemicals |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D019086 | Bridged Bicyclo Compounds, Heterocyclic |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| Somewhat dissatisfied |
|
| Neither satisfied nor dissatisfied |
|
| Somewhat satisfied |
|
| Satisfied |
|
| Very Satisified |
|
| Dissatisfied |
|
| Somewhat dissatisfied |
|
| Neither satisfied nor dissatisfied |
|
| Somewhat satisfied |
|
| Satisfied |
|
| Very satisfied |
|
| Not applicable |
|
| Q2: How satisfied are you with the grip of the cartridge? |
|
|
| Q3: How satisfied are you with inserting a new cartridge? |
|
|
| Q4: How satisfied are you with the readability of the dose indicator? |
|
|
| Q5: How satisfied are you with recognising when you need to replace the cartridge? |
|
|
| Q6: How satisfied are you with automatic detachment of the clear base when the cartridge is empty? |
|
|
| Q7: How satisfied are you with automatic return to start-use position when replacing the clear base? |
|
|
| Q8: How satisfied are you with the overall ease of handling the inhaler? |
|
|
| Q9: How satisfied are you with the sustainability concept of the inhaler, due to re-use ability? |
|
|
| Q10: How satisfied are you with recognising when to replace the inhaler? |
|
|